Pectolinarigenin

Synonyms: 柳穿鱼黄素
Pectolinarigenin 是一种具有口服活性的 COX-2/5-LOX 双重抑制剂,具有抗炎、抗氧化、抗肿瘤和神经保护活性,它通过 NFκB 和 MAPK 通路对星形胶质细胞炎症发挥神经保护和抗炎作用,可抑制 LPS 诱导的 ERK1/2、NFκB 和 p38MAPK 磷酸化,直接抑制 COX-2、5-LOX 和 HIF-1α 的酶活性或结合作用,并降低 XIAP 水平,还可修饰 Keap1 以促进 Nrf2 的核蓄积,诱导 ARE 介导的抗氧化酶表达,且具有直接的自由基清除能力,同时可减少 NO、促炎介质和白三烯的释放,提高 IL-10 水平,并通过 PI3K/AKT/mTOR 信号通路诱导 G2/M 期细胞周期阻滞、细胞凋亡 (Apoptosis) 和自噬 (Autophagy),此外还能减少肾结晶沉积、抑制黑色素合成,在小鼠炎症模型中可抑制炎症、缓解过敏,并通过抑制 HIF-1α 活性缓解小鼠肾损伤、炎症及氧化应激,因此可用于神经退行性疾病、炎症/过敏性疾病、草酸钙肾钙质沉着症、胃癌、黑皮病、炎症后疾病和黄褐斑的研究。
产品编号: MS-M28707 纯度: 99.98% CAS No.: 520-12-7 分子式: C17H14O6 分子量: 314.29
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
20mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Pectolinarigenin 是一种具有口服活性的 COX-2/5-LOX 双重抑制剂,具有抗炎、抗氧化、抗肿瘤和神经保护活性,它通过 NFκB 和 MAPK 通路对星形胶质细胞炎症发挥神经保护和抗炎作用,可抑制 LPS 诱导的 ERK1/2、NFκB 和 p38MAPK 磷酸化,直接抑制 COX-2、5-LOX 和 HIF-1α 的酶活性或结合作用,并降低 XIAP 水平,还可修饰 Keap1 以促进 Nrf2 的核蓄积,诱导 ARE 介导的抗氧化酶表达,且具有直接的自由基清除能力,同时可减少 NO、促炎介质和白三烯的释放,提高 IL-10 水平,并通过 PI3K/AKT/mTOR 信号通路诱导 G2/M 期细胞周期阻滞、细胞凋亡 (Apoptosis) 和自噬 (Autophagy),此外还能减少肾结晶沉积、抑制黑色素合成,在小鼠炎症模型中可抑制炎症、缓解过敏,并通过抑制 HIF-1α 活性缓解小鼠肾损伤、炎症及氧化应激,因此可用于神经退行性疾病、炎症/过敏性疾病、草酸钙肾钙质沉着症、胃癌、黑皮病、炎症后疾病和黄褐斑的研究。

生物实验数据

生物活性 Pectolinarigenin is an orally active dual COX-2/5-LOX inhibitor with anti-inflammatory, antioxidant, antitumor, and neuroprotective activities; it exerts neuroprotective and anti-inflammatory effects on astrocyte inflammation through the NFκB and MAPK pathways, inhibits LPS-induced phosphorylation of ERK1/2, NFκB, and p38MAPK, directly inhibits the enzymatic activity or binding of COX-2, 5-LOX, and HIF-1α, and reduces XIAP levels; it also modifies Keap1 to promote nuclear accumulation of Nrf2, induces ARE-mediated antioxidant enzyme expression, and possesses direct free radical scavenging capacity; furthermore, it reduces the release of NO, pro-inflammatory mediators, and leukotrienes while increasing IL-10 levels, induces G2/M phase cell cycle arrest, apoptosis, and autophagy through the PI3K/AKT/mTOR signaling pathway, reduces renal crystal deposition, inhibits melanin synthesis, suppresses inflammation and alleviates allergy in mouse inflammation models, and alleviates renal injury, inflammation, and oxidative stress in mice by inhibiting HIF-1α activity; therefore, it can be used for research on neurodegenerative diseases, inflammatory/allergic diseases, calcium oxalate nephrocalcinosis, gastric cancer, melanoderma, post-inflammatory conditions, and chloasma.
IC50 & Target

COX-2

 

5-LOX

 

体外研究
(In Vitro)

Pectolinarigenin (5-160 μM; 24 h) 在 160 μM 浓度下会降低 J774A.1 小鼠巨噬细胞存活率,可抑制 LPS (MS-X54539) 诱导的 J774A.1 小鼠巨噬细胞中 NO 的释放。
Pectolinarigenin (1-5 μM; 1 h pre-incubation plus 24 h incubation) 可抑制 LPS 诱导的原代小鼠大脑皮层星形胶质细胞活化、抑制细胞中 IL-1β 和 IL-6 的释放,升高基础 IL-10 水平,并恢复被脂多糖降低的 IL-10 水平。
Pectolinarigenin (5 μM; 1 h pre-incubation plus 0.5-1 h incubation) 可抑制脂多糖诱导的原代小鼠大脑皮层星形胶质细胞中 NFκB、ERK1/2、p38MAPK 的激活。
Pectolinarigenin (1-50 μM; 24 h, 15 min) 可浓度依赖性地抑制 LPS 刺激的 RAW 264.7 细胞中 COX-2 介导的 PGE2 生成,在 50 μM 作用 24 h 时抑制率达 99.0%,并可直接抑制 COX-2 的酶活性 (50 μM 作用 15 min 时抑制率为 44.8%)。
Pectolinarigenin (1-50 μM; 10 min pre-incubation + 15 min A23187 (MS-X54063) incubation) 可剂量依赖性地抑制经 A23187 刺激的 RBL-1 细胞中由 5-LOX 介导的半胱氨酰白三烯生成,在 50 μM (10 min pre-incubation + 15 min A23187 incubation) 浓度下抑制率达 97.0%。
Pectolinarigenin (0.1-10 μM; 24 h) 可显著抑制 AAPH (MS-W29187) 诱导的 HepG2 细胞依赖于 Nrf2 通路的 ROS 的积累。
Pectolinarigenin (0.1-10 μM; 24 h) 可诱导 HepG2 细胞中抗氧化酶的表达:上调血红素加氧酶-1 的表达,而 10 μM 浓度可上调 NAD (P) H:quinone oxidoreductase 1 和 aldo-keto reductase 家族 1 成员 B10 的表达。
Pectolinarigenin (0.1-10 μM; 3-24 h) 可显著促进 HepG2 细胞中 Nrf2 的核内聚集,以及增强 ARE 介导的转录活性。
Pectolinarigenin (2-8 μM; 12 h pretreatment, followed by COM stimulation) 可浓度依赖性地抑制 COM 诱导的 HK-2 细胞中 KIM-1 mRNA 及蛋白表达水平升高,抑制细胞炎症反应。
Pectolinarigenin (8 μM; 12 h pretreatment, followed by COM stimulation) 可通过恢复抗氧化标志物水平 (GSH、HO-1、GPX4) 并降低促氧化标志物水平 (MDA、铁、ROS),减轻 COM 诱导的 HK-2 细胞氧化应激损伤。
Pectolinarigenin (8 μM; 12 h incubation) 可抑制 HK-2 细胞中的 HIF-1α 活性。
Pectolinarigenin (8 μM; 12 h pretreatment, followed by COM stimulation) 以体外 HIF-1α 依赖的方式减轻 COM 诱导的 HK-2 细胞肾损伤、炎症和氧化应激,因为当 HIF-1α 被敲低时,其保护作用会消失。
Pectolinarigenin (25-150 μM; 24 h) 可剂量依赖性地抑制 AGS 和 MKN28 人胃癌细胞的活力,其 IC50 值分别为 124.79 μM 和 96.88 μM。
Pectolinarigenin (50-100 μM; 24 h) 可诱导人胃癌细胞系 AGS 和 MKN28 发生 G2/M 期细胞周期阻滞,同时在 AGS 细胞中伴随亚 G1 期细胞堆积 (提示细胞凋亡),其作用机制为下调 CDK1 和 CDC25C 的蛋白表达水平,并上调 p53 和 p21 的 mRNA 表达水平。
Pectolinarigenin (50-100 μM; 24 h) 可通过下调 XIAP 并激活 caspase-PARP 凋亡通路,在人胃癌细胞系 AGS 和 MKN28 中诱导剂量依赖性凋亡。
Pectolinarigenin (50-100 μM; 24 h) 可在人胃癌细胞系 AGS 和 MKN28 中诱导不依赖 Beclin-1 的自噬。
Pectolinarigenin (50-100 μM; 24 h) 可呈剂量依赖性地抑制人胃癌细胞株 AGS 和 MKN28 中的 PI3K/AKT/mTOR 信号通路,进而降低下游通路靶点 p70S6K、4EBP1 及 eIF4E 的磷酸化水平。
Pectolinarigenin (30 μM; 72 h) 可显著降低 melan-a 细胞中的黑色素含量、酪氨酸酶活性,降低酪氨酸酶、TRP-1、TRP-2 和 MITF 的蛋白表达水平,降低细胞中 tyrosinase、TRP-1 和 MITF 的 mRNA 表达水平。
Pectolinarigenin (30 μM; 2 days) 可显著将重组人皮肤模型中的黑色素含量降至对照组的 20.8%,并降低 L-DOPA 含量。

Cell Viability Assay

Cell Line: J774A.1 murine macrophages
Concentration: 5, 10, 20, 40, 80, 160 μM
Incubation Time: 24 h
Result: Decreased cell viability at 160 μM.
Did not reduce cell viability relative to controls at concentrations below 80 μM.

Immunofluorescence

Cell Line: astrocytes primary culture
Concentration: 5 μM
Incubation Time: 1 h pre-incubation plus 24 h incubation
Result: Restored the structure of damaged filamentous collagen acidic protein (GFAP)

Western Blot Analysis

Cell Line: human hepatoma HepG2 cells
Concentration: 0.1, 1.0, 10 μM
Incubation Time: 24 h
Result: Significantly increased protein expression of heme oxygenase-1 at all tested concentrations.
Significantly increased protein expression of NAD(P)H:quinone oxidoreductase 1 and aldo-keto reductase family 1 member B10 at 10 μM.

Western Blot Analysis

Cell Line: human hepatoma HepG2 cells
Concentration: 0.1, 1.0, 10 μM
Incubation Time: 3 h
Result: Significantly increased nuclear accumulation of Nrf2 at all tested concentrations, with levels normalized to Lamin B.

Cell Viability Assay

Cell Line: AGS, MKN28 cells
Concentration: 25, 50, 75, 100, 125, 150 μM
Incubation Time: 24 h
Result: Inhibited cell growth in a dose-dependent manner in both cell lines.
Reached IC50 values of 124.79 μM for AGS cells and 96.88 μM for MKN28 cells after 24 h of treatment.
Caused massive cell rounding, shrinkage, and detachment from culture plates at 50 and 100 μM after 24 h of treatment.

Cell Cycle Analysis

Cell Line: AGS, MKN28 cells
Concentration: 50, 100 μM
Incubation Time: 24 h
Result: Caused significant accumulation of cells in the G2/M phase in both AGS and MKN28 cells.
Induced a significant increase in sub-G1 phase cells (indicative of apoptotic death) in AGS cells, while inducing a slight increase in sub-G1 phase cells in MKN28 cells.
Downregulated CDK1 and CDC25C protein expression in a dose-dependent manner at 50 and 100 μM.
Increased p53 and p21 mRNA levels in a significant dose-dependent manner in both cell lines, with no significant changes in p53 and p21 protein levels.

Apoptosis Analysis

Cell Line: AGS, MKN28 cells
Concentration: 50, 100 μM
Incubation Time: 24 h
Result: Induced dose-dependent apoptosis in both cell lines.
Increased total apoptotic cells by over 6-fold in AGS cells (with early apoptosis as the major population) and over 5-fold in MKN28 cells (with late apoptosis as the major population) at 100 μM after 24 h.
Showed fragmented or condensed nuclei in treated cells via Hoechst 33342 staining, confirming apoptotic death.
Downregulated XIAP, procaspase-8, procaspase-7, and procaspase-3 in a dose-dependent manner, with concurrent upregulation of cleaved caspase-3, cleaved caspase-7, and cleaved PARP in both cell lines.

Cell Autophagy Assay

Cell Line: AGS, MKN28 cells
Concentration: 50, 100 μM
Incubation Time: 24 h
Result: Induced dose-dependent formation of acidic vesicular organelles (AVOs) in both cell lines.
Increased the LC3-II/LC3-I ratio and p62 expression in a dose-dependent manner, with concurrent dose-dependent downregulation of Beclin-1 expression in both cell lines.

Western Blot Analysis

Cell Line: melan-a cells
Concentration: 30 μM
Incubation Time: 72 h
Result: Reduced protein expression of tyrosinase to 37.9%.
Reduced protein expression of TRP-1 to 42.0%.
Reduced protein expression of TRP-2 to 38.3%.
Reduced protein expression of MITF to 51.5%.

Real Time qPCR

Cell Line: melan-a cells
Concentration: 30 μM
Incubation Time: 72 h
Result: Reduced mRNA expression of tyrosinase to 55.0%.
Reduced mRNA expression of TRP-1 to 10.7 %.
Reduced mRNA expression of MITF to 32.3 %.
体内研究
(In Vivo)

Pectolinarigenin (4-100 mg/kg; p.o.; single dose) 以 100 mg/kg 经口给药时,可对 Arachidonic acid (MS-A69140) 诱导的小鼠耳水肿产生抑制作用。
Pectolinarigenin (4-100 mg/kg; p.o.; single dose) 以 100 mg/kg 经口给药时,对角叉菜胶诱导的小鼠足肿胀产生 21.1% 的抑制作用。
Pectolinarigenin (20 mg/kg; p.o.; two doses) 以 20 mg/kg 的剂量经口给药两次,可对大鼠的被动皮肤过敏反应产生 30.8%的抑制作用。
Pectolinarigenin (1.0-10 mg/kg; p.o.; daily; 7 days) 以 10 mg/kg 的剂量经口每日给药 7 天时,可激活雄性 ICR 小鼠肝脏中的 Nrf2/ARE 通路,显著诱导抗氧化酶的表达并促进 Nrf2 核转位。
Pectolinarigenin (7.25-25 mg/kg; i.g.; daily) 可通过抑制 HIF-1α 活性,以剂量依赖的方式缓解草酸钙诱导的小鼠肾损伤、炎症及氧化应激。

Animal Model: ICR (male, 4 weeks old, specific pathogen-free)
Dosage: 4 mg/kg; 20 mg/kg; 100 mg/kg
Administration: p.o.; single dose
Result: Reduced increased ear thickness by 18.7% at 20 mg/kg.
Produced a statistically significant 34.7% inhibition of increased ear thickness at 100 mg/kg.\n
Reduced increased paw volume by 2.6% at 4 mg/kg.
Reduced increased paw volume by 13.2% at 20 mg/kg.
Reduced increased paw volume by 21.1% at 100 mg/kg.
Animal Model: Sprague-Dawley (male, 4 weeks old, specific pathogen-free)
Dosage: 20 mg/kg
Administration: p.o.; two doses (1 hour before IgE injection and 1 hour before antigen challenge)
Result: Produced a 30.8% inhibition of the allergic response.
Animal Model: ICR mice (male, 6-week-old)
Dosage: 1.0 mg/kg; 10 mg/kg
Administration: p.o.; daily; 7 days
Result: Significantly increased liver protein expression of heme oxygenase-1 (HO-1) and aldo-keto reductase family 1 member B10 (AKR1B10), and significantly promoted nuclear translocation of nuclear factor-erythroid-2-related factor 2 (Nrf2) in the liver at 10 mg/kg.
Did not produce statistically significant increases in HO-1, AKR1B10 expression, or Nrf2 nuclear translocation at 1.0 mg/kg.
Reached plasma concentrations of 0.92 μM (1.0 mg/kg group) and 1.09 μM (10 mg/kg group) 2 hours after the final dose.
Animal Model: C57BL/6J mice (male, 6-8 weeks old, 22-24 g)
Dosage: 7.25 mg/kg; 12.5 mg/kg; 25 mg/kg
Administration: i.g.; daily
Result: Reduced serum creatinine and blood urea nitrogen (BUN) levels in a concentration-dependent manner.
Attenuated renal tubular damage (assessed via PAS staining) and reduced renal calcium oxalate crystal deposition in a concentration-dependent manner.
Inhibited the glyoxylate-induced increase in KIM-1 protein and mRNA expression.
Impeded the glyoxylate-induced elevation of inflammatory factors (IL-6, MCP-1, TNF-α) at the mRNA level, and inhibited phosphorylation of P65.
Reduced renal malondialdehyde (MDA) and iron levels, and increased reduced glutathione (GSH) levels, in a concentration-dependent manner.
Upregulated renal expression of HO-1 and GPX4 proteins.
Inhibited the activity of HIF-1α (assessed via luciferase reporter assay) without reducing HIF-1α protein or mRNA expression.
性状 固体
颜色 Light yellow to yellow

化学信息

分子量 314.29
分子式 C17H14O6
CAS No. 520-12-7
别名 柳穿鱼黄素

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 0.96 mg/mL (3.05 mM), Solution.
10% DMSO+90% Saline: 2.50 mg/mL (7.95 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, protect from light

*In solvent: -80°C, 6 months; -20°C, 1 month (protect from light)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 33.33 mg/mL (106.05 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.1818 mL15.9089 mL31.8177 mL79.5444 mL
5 mM0.6364 mL3.1818 mL6.3635 mL15.9089 mL
10 mM0.3182 mL1.5909 mL3.1818 mL7.9544 mL
15 mM0.2121 mL1.0606 mL2.1212 mL5.3030 mL
20 mM0.1591 mL0.7954 mL1.5909 mL3.9772 mL
25 mM0.1273 mL0.6364 mL1.2727 mL3.1818 mL
30 mM0.1061 mL0.5303 mL1.0606 mL2.6515 mL
40 mM0.0795 mL0.3977 mL0.7954 mL1.9886 mL
50 mM0.0636 mL0.3182 mL0.6364 mL1.5909 mL
60 mM0.0530 mL0.2651 mL0.5303 mL1.3257 mL
80 mM0.0398 mL0.1989 mL0.3977 mL0.9943 mL
100 mM0.0318 mL0.1591 mL0.3182 mL0.7954 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础